BioSante Pharmaceuticals To Present At Amex Healthcare & Biotech Investor Conference and Barron's Informed Investors Forum.LINCOLNSHIRE, Ill. -- BioSante Pharmaceuticals, Inc. (Amex:BPA BPA British Paediatric Association. ) announced today that Stephen M. Simes, its president and chief executive officer, will present at the American Stock Exchange American Stock Exchange (AMEX) Stock exchange in the U.S. Originally known as “the Curb,” it began as an outdoor marketplace in New York City c. 1850. It moved indoors to its present location in the Wall Street area in 1921. Annual Online Healthcare & Biotech Investor Conference on June 22, 2004 at 9 a.m. EDT EDT abbr. Eastern Daylight Time EDT Eastern Daylight Time EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York EDT . The presentation can be webcast at www.vcall.com/CEPage.asp?ID=88398 and will be archived at www.vcallconferences.com/conferences/AMEX/0622-29-2004/ index.asp?ID=88206. Mr. Simes also will be presenting at the Barron's sponsored Informed Investors Biotechnology and Pharmaceutical Stocks Forum in New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of on Wednesday, June 23, at 1:30 p.m. EDT. A webcast of the forum will be archived on www.informedinvestors.com following the event. Mr. Simes will discuss the company and its product development pipeline of hormone therapies and nanotechnology-based vaccines and drug delivery systems. About BioSante Pharmaceuticals, Inc. BioSante is developing a pipeline of hormone therapy products to treat both men and women. BioSante's hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. Symptoms treated with hormone therapy in men include impotence, diminished sex drive, muscle weakness and osteoporosis. Symptoms in menopausal women include hot flashes hot flashes Hot flush Gynecology A symptom afflicting 80-85% of middle-aged ♀, first occurring during the perimenopause, continuing with ↓ intensity for yrs, manifesting itself as transient waves of erythema and uncomfortable warmth beginning in the , vaginal atrophy vaginal atrophy Atrophic vaginitis, see there , decreased libido and osteoporosis. The estrogen and testosterone markets in the United States alone account for over $2.5 billion in annual sales. The company also is developing its calcium phosphate nanotechnology (CAP) for novel vaccines, including biodefense vaccines for toxins such as anthrax and ricin ricin /ri·cin/ (ri´sin) a phytotoxin in the seeds of the castor oil plant (Ricinus communis), used in the synthesis of immunotoxins. ri·cin n. , and drug delivery systems. Additional information is available online at www.biosantepharma.com. This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The statements regarding BioSante contained in this press release that are not historical in nature, particularly those that utilize terminology such as "may," "will," "should," "likely," "expects," "anticipates," "estimates," "believes" or "plans," or comparable terminology, are forward-looking statements. Forward-looking statements are based on current expectations and assumptions, and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to BioSante that cause actual results to differ materially from those expressed in such forward-looking statements are the difficulty of developing pharmaceutical products and especially new vaccines, obtaining regulatory and other approvals and achieving market acceptance, and other factors identified and discussed from time to time in BioSante's filings with the Securities and Exchange Commission, including those factors discussed on pages 18 to 25 of BioSante's Form 10-KSB, which discussion also is incorporated herein by reference. For more information, please contact: Phillip B. Donenberg, CFO See Chief Financial Officer. , 847-478-0500 ext 101 |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion